SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
JNJ Analysis & Videos »
JNJ: Bull or Bear?
Where should granny put $50,000?
JNJ
|
|
|
-0.83%
in
33 days
Filed under: Getting started, McDonald's (MCD), Diageo plc (DEO), Johnson and Johnson (JNJ), Altria Group (MO), Novartis AG ADS (NVS), Automatic Data Proc (ADP), Kellogg Co (K), Consolidated Edison (ED), General Mills (GIS), Procter and Gamble (PG), Merck and Co (MRK), Duke Energy (DUK), Personal finance, S and P 500, Stocks to Buy, Southern Company (SO), Annaly Capital Management (NLY) <> One of my wonderful friends, Ms. P, asked me for some guidance on how she might allocate $50,000 currently earning peanuts in a money market account. Though she is decades from becoming a grandmother, after a...
|
Cramer on BloggingStocks: You can't afford to be certain
JNJ
+0.12%
in
103 days
<>Filed under: Apple Inc (AAPL), Hewlett-Packard (HPQ), Ford Motor (F), Market matters, Walt Disney (DIS), International Business Machines (IBM), AT and T (T), 3M Corporation (MMM), Caterpillar (CAT), Schlumberger Limited (SLB), Citigroup Inc. (C), Johnson and Johnson (JNJ), JPMorgan Chase (JPM), Bank of America (BAC), Bed Bath and Beyond (BBBY), Best Buy (BBY), FedEx Corp (FDX), Verizon Communications (VZ), Lennar Corp'A' (LEN), United Parcel'B' (UPS), Anadarko Petroleum (APC), Wells Fargo (WFC), Stocks to Buy, Norfolk Southern Corp. (NSC), Union Pacific Corporation (UNP), <>Cramer on Blogging...
|
BioMedReports: FDA Calendar Updates
JNJ
|
|
|
+3.85%
in
119 days
<> Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 260 entries as of 7/15/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clini...
|
FDA Calendar Updates: ABII, BMRN, JNJ, OSIP, Roche
JNJ
|
|
|
+2.22%
in
2 days
(closed on 07/15/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 254 entries as of 7/13/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
FDA, Clinical Trial Updates: Heart Stents, Cholesterol in the News
JNJ
|
|
|
+3.24%
in
54 days
(closed on 07/13/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA Calendar Updates: ACUS, APPY, APPA, ALKS, JNJ
JNJ
|
|
|
-0.32%
in
2 days
(closed on 05/20/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Johnson & Johnson (JNJ): 'A buy for any portfolio'
JNJ
+19.93%
in
91 days
(closed on 07/29/09)
Filed under: International markets, Newsletters, Johnson and Johnson (JNJ), DJIA, Stocks to Buy "Health-care stocks have been volatile of late, as the prospects for significant healthcare reform are impacting the group," notes Chuck Carlson. In The DRIP Investor, he explains, "Johnson & Johnson (NYSE: JNJ) has not been immune to the weakness. And while these shares could remain under pressure in the short run, the company's prospects are significantly brighter than the typical health-care stock." <>"First, Johnson & Johnson's diversified business portfolio, which includes pharmaceuticals, medica...
|
FDA, Clinical Trial Updates: Pro-Pharma Looks Promising
JNJ
|
|
|
+9.22%
in
24 days
(closed on 05/18/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Updated Clinical Trial and FDA Decision Calendars
JNJ
|
|
|
-2.12%
in
24 days
(closed on 04/13/09)
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
People Bullish on JNJ
People Bearish on JNJ
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
|
|
|
|
fas831
(-8.08% risk: conservative)
|
|
Johnson & Johnson vs 3M
- I have been waiting and waiting for JNJ to drop but its really dissapointing seeing such a steady stock..on the other hand is 3M who is JNJ's competito
|
More Resources
|
About Johnson & Johnson
- Answers.com
Billions of investment dollars are sitting on the sidelines for fear of entering the market at the wrong time and losing more money after taking a bath last year. However, the market seems to have hit bottom last March and many investors missed the 40% gain from that point to now.
Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models, who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, 
